title: Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
abstract: Neuroendocrine tumors (NETs) are associated with variable prognosis, with grade 1 and 2 NETs having more favorable outcomes than grade 3. Patients with gastroenteropancreatic (GEP)-NET need individualized interdisciplinary evaluations and treatment. New treatment options have become available with significant improvements in progression-free survival. Peptide receptor radionuclide therapy (PRRT) using (90)Y or (177)Lu-labeled somatostatin analogues (SSTa) has also shown promise in the treatment of advanced progressive NETs. (68)Ga-1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA)-SSTa can be used as companion imaging agents to assist in radionuclide therapy selection. (68)Ga-DOTA-SSTa PET/computed tomography might also provide information for prognosis, tumor response assessment to PRRT, and internal dosimetry.
authors.affiliation: Department of Nuclear Medicine, La Timone University Hospital, Aix-Marseille University, 264, rue Saint-Pierre, Marseille 13385, France; European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France; Marseille Cancerology Research Center, Inserm UMR1068, Institut Paoli-Calmettes, Marseille, France. Electronic address: david.taieb@ap-hm.fr.
authors.forename: David
authors.initials: D
authors.lastname: Taïeb
authors.affiliation: Department of Radiopharmacy, La Timone University Hospital, Aix-Marseille University, Marseille, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Garrigue
authors.affiliation: UMR 1037 Inserm/UPS, Cancer Research Center of Toulouse, Toulouse, France.
authors.forename: Manuel
authors.initials: M
authors.lastname: Bardiès
authors.affiliation: Department of Nuclear Medicine, La Timone University Hospital, Aix-Marseille University, 264, rue Saint-Pierre, Marseille 13385, France.
authors.forename: Ahmad Esmaeel
authors.initials: AE
authors.lastname: Abdullah
authors.affiliation: Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Karel
authors.initials: K
authors.lastname: Pacak
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D004067:Digestive System Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000532:radiotherapy*; D005710:Gallium Radioisotopes / Q000493:pharmacokinetics; D006801:Humans; D007553:Isotope Labeling; D064847:Multimodal Imaging / Q000379:methods; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000532:radiotherapy*; D049268:Positron-Emission Tomography / Q000379:methods; D011379:Prognosis; D011874:Radiometry / Q000379:methods; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D061089:Radiotherapy, Image-Guided / Q000379:methods; D017481:Receptors, Somatostatin / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D013004:Somatostatin
keywords: Gallium radioisotopes; Gastroenteropancreatic; Neuroendocrine; PET; Somatostatin